Maxim Group Downgrades VistaGen Therapeutics (VTGN) to Hold
Tweet
Share
E-mailGet Alerts VTGN Hot Sheet
Price: $0.27 --0%
Rating Summary:
2 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Maxim Group analyst Caroline Palomeque downgraded VistaGen Therapeutics (NASDAQ: VTGN) from Buy to Hold.
For an analyst ratings summary and ratings history on VistaGen Therapeutics click here. For more ratings news on VistaGen Therapeutics click here.
Shares of VistaGen Therapeutics closed at $0.18 yesterday.
You May Also Be Interested In
- Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
- Barclays Downgrades Murphy Oil Corp. (MUR) to Underweight
- DA Davidson Downgrades Blaize Inc. (BZAI) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
